BioPlus Acquisition Corp.

BioPlus Acquisition Corp. (Nasdaq: BIOS) is a blank check company that pursued its initial public offering in 2021, focusing on acquisition targets in the healthcare and life sciences sector. The company filed an amended registration statement on Form S-1/A with the SEC on November 29, 2021, under accession number 0001193125-21-341355, reflecting ongoing refinements to its offering terms ahead of pricing. Organized as a Cayman Islands-incorporated special purpose acquisition company, BioPlus was structured to identify and consummate a business combination with a target in the biotechnology, pharmaceutical, or related life sciences industries. Investors seeking the full filing history, deal timeline, sponsor background, and current status for BioPlus Acquisition Corp. can access comprehensive data by signing up at SpacDesk.